Friday, October 30, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared

View original at finance.yahoo.com
JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared Lamb Weston Holdings, Inc. (NYSE:LW) is one of the 10 Best Stocks That Beat Earnings Estimates…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The quarter was supported by continued strength in North America and disciplined execution, while highlighting ongoing efforts to align supply and demand and manage a competitive international environment

    60% confidence

  • Certain AI stocks offer greater upside potential and carry less downside risk than Lamb Weston

    60% confidence

  • Lamb Weston delivered a Q3 EPS beat, driven by stronger-than-expected performance in North America that offset international weakness, higher interest expense, and tax impacts

    60% confidence

  • The results were better than feared, noting the company narrowed its full-year EBITDA guidance while raising the midpoint, signaling stabilization in North America alongside more predictable international pressures

    60% confidence

  • JPMorgan maintained a Neutral rating on Lamb Weston shares

    60% confidence

  • The outlook reflects currency benefits, tariff impacts, ongoing disruption in parts of the Middle East, and the inclusion of a 53rd week in fiscal 2026

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
JPMorgan Says Lamb Weston Holdings (LW) Q3 Results Were Better Than Feared — Source | Via News | Finance Via News